Bristol-Myers (BMY) sBLA for Empliciti Gets Priority Review

Bristol-Myers Squibb Company BMY announced that the FDA has accepted the supplemental Biologics License Application (sBLA) seeking label expansion of multiple myeloma drug, Empliciti (elotuzumab). The sBLA seeks approval of Empliciti in combination with Celgene’s CELG Pomalyst (pomalidomide) and low-dose dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma (r/rMM) in second- or later-line settings.